SAB Biotherapeutics 404280DR7 Bond
SABS Stock | USD 3.07 0.01 0.33% |
SAB Biotherapeutics holds a debt-to-equity ratio of 0.164. At this time, SAB Biotherapeutics' Long Term Debt is comparatively stable compared to the past year. Net Debt To EBITDA is likely to gain to 1.39 in 2024, despite the fact that Net Debt is likely to grow to (48.1 M). . SAB Biotherapeutics' financial risk is the risk to SAB Biotherapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
SAB Biotherapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. SAB Biotherapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps SAB Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect SAB Biotherapeutics' stakeholders.
For most companies, including SAB Biotherapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for SAB Biotherapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, SAB Biotherapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 0.7678 | Book Value 3.998 | Operating Margin (34.23) | Return On Assets (0.79) | Return On Equity (1.75) |
SAB |
Given the importance of SAB Biotherapeutics' capital structure, the first step in the capital decision process is for the management of SAB Biotherapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of SAB Biotherapeutics to issue bonds at a reasonable cost.
Popular Name | SAB Biotherapeutics HSBC Holdings PLC |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | US78397T1034 |
Bond Issue ISIN Code | US404280DR76 |
S&P Rating | Others |
Maturity Date | 3rd of November 2028 |
Issuance Date | 3rd of November 2022 |
Coupon | 7.39 % |
SAB Biotherapeutics Outstanding Bond Obligations
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
HYUELE 6375 17 JAN 28 | US78392BAE74 | Details | |
HYUELE 15 19 JAN 26 | US78392BAB36 | Details | |
MGM Resorts International | US552953CD18 | Details | |
US78390XAC56 | US78390XAC56 | Details | |
SECBEN 65 | US78397DAC20 | Details | |
SECBEN 7 | US78397DAA63 | Details | |
SECBEN 5 18 FEB 31 | US78397DAB47 | Details | |
US78397UAA88 | US78397UAA88 | Details |
Understaning SAB Biotherapeutics Use of Financial Leverage
SAB Biotherapeutics' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to SAB Biotherapeutics' current equity. If creditors own a majority of SAB Biotherapeutics' assets, the company is considered highly leveraged. Understanding the composition and structure of SAB Biotherapeutics' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 5.9 M | 5.5 M | |
Net Debt | -50.7 M | -48.1 M | |
Long Term Debt | 622.9 K | 654 K | |
Short and Long Term Debt | 1.1 M | 604.8 K | |
Short Term Debt | 2.7 M | 2.1 M | |
Net Debt To EBITDA | 1.33 | 1.39 | |
Debt To Equity | 0.03 | 0.03 | |
Interest Debt Per Share | 0.39 | 0.35 | |
Debt To Assets | 0.02 | 0.02 | |
Long Term Debt To Capitalization | 0.02 | 0.02 | |
Total Debt To Capitalization | 0.03 | 0.03 | |
Debt Equity Ratio | 0.03 | 0.03 | |
Debt Ratio | 0.02 | 0.02 | |
Cash Flow To Debt Ratio | (13.56) | (12.88) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.